Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
The New England journal of medicine 2018 09 25() doi 10.1056/NEJMoa1809697 Abstract BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with...
Read More